目的 觀察注射用丹參多酚酸聯(lián)合阿替普酶治療急性腦梗死的療效及預(yù)后。方法 選取安陽市中醫(yī)院于2019年1月-2020年1月期間收治的急性腦梗死溶栓患者85例為研究對(duì)象。采用隨機(jī)數(shù)字表法將患者分為對(duì)照組（40例）和觀察組（45例）。對(duì)照組使用注射用阿替普酶進(jìn)行靜脈溶栓治療，最大劑量90 mg/d，首次注射1 min內(nèi)先將阿替普酶劑量的10%靜脈推注，剩余劑量在60 min內(nèi)使用微量泵持續(xù)泵入。觀察組在溶栓完畢后立即靜脈滴注注射用丹參多酚酸，130 mg/次，1次/d，共治療14 d。對(duì)比兩組患者治療后的神經(jīng)功能、預(yù)后及安全性。結(jié)果 治療后，對(duì)照組和觀察組有效率分別為77.5%和93.3%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組和觀察組的美國國立衛(wèi)生研究院卒中量表評(píng)分（NIHSS）中位數(shù)為4.5（1，9.25）和3（1，4），兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療90 d內(nèi)，兩組不良事件發(fā)生率分別為7.5%和6.7%，兩組間比較差異無統(tǒng)計(jì)學(xué)意義；死亡率比較差異無統(tǒng)計(jì)學(xué)意義。治療90 d后，兩組分別有20例（50%）、33例（73.3%）患者預(yù)后良好，兩組治療后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 急性腦梗死超急性期溶栓后加用注射用丹參多酚酸，可改善患者的神經(jīng)功能，且不增加出血及死亡風(fēng)險(xiǎn)。

Objective To observe the efficacy and prognosis of Salvianolic Acids for Injection combined with alteplase in treatment of acute cerebral infarction. Methods A total of 85 patients with acute cerebral infarction admitted to Anyang Hospital of Traditional Chinese Medicine from January 2019 to January 2020 were selected as the study subjects. Patients were divided into control group (40 cases) and observation group (45 cases) by random number table method. Patients in the control group were treated with intravenous thrombolysis with Alteplase for Injection at a maximum dose of 90 mg/d, 10% of alteplase was injected intravenously within 1 min of the first injection, and the remaining dose of alteplase was continuously pumped with a micro pump within 60 min. Patients in the control group were intravenous infusion of Salvianolic Acids for Injection, 130 mg/d once daily administered immediately after thrombolysis for 14 days. After treatment, the neurological function, prognosis and safety of two groups were compared. Results After treatment, the effective rates of the control group and observation group were 77.5% and 93.3%, respectively, with statistically significant differences between the two groups (P<0.05). After treatment, the median NIHSS score in two groups was 4.5 (1, 9.25) and 3 (1, 4), respectively, and the difference between two groups was statistically significant (P<0.05). Within 90 days of treatment, the incidence of adverse events in two groups was 7.5% and 6.7%, respectively, with no statistically significant difference between two groups. And there was no statistically significant difference in mortality. After 90 days of treatment, 20 patients (50%) and 33 patients (73.3%) in two groups respectively had a good prognosis, and the difference between two groups after treatment was statistically significant (P<0.05). Conclusion After hyperacute thrombolysis of acute cerebral infarction, the usage of Salvianolic Acids for Injection can improved neurological function, without increasing the risk of bleeding or death.

R971